AZD1163 for Rheumatoid Arthritis
A Study to Investigate Efficacy and Safety of AZD1163 in Participants With Rheumatoid Arthritis
- Age
- 18 and older
- Sex
- Any
- Trial phase
- Phase 2
- Study type
- Interventional
- Purpose
- Treatment
- Participants needed
- 320 (estimated)
- Sponsor
- AstraZeneca · Industry
This trial is looking for people with moderately-to-severely active rheumatoid arthritis. Participants will be evaluated for how well the medication AZD1163 works and its safety.
You may be able to join if
- I have been diagnosed with rheumatoid arthritis for at least 12 weeks.
- I have at least 6 swollen joints and 6 tender joints.
- My CRP levels are above normal.
- I have a positive ACPA test.
- I have not responded well to at least one csDMARD treatment or 1-2 TNFi.
- I have been on a stable dose of csDMARD or SC TNFi for at least 4 weeks.
You may not be able to join if
- I have a history of another autoimmune condition that could confuse my RA diagnosis.
- I plan to receive any biologic DMARDs (other than TNFi).
- I have received any targeted synthetic DMARDs.
Summarized in plain language from this trial's official eligibility criteria. The full criteria are further down this page — only the research team can confirm whether you qualify.
Think this trial could be right for you?
Answer three quick questions written from this study's own rules to see if you may qualify. No account needed to find out.
Check Your EligibilityPhase II study in participants with moderately-to-severely active rheumatoid Arthritis (RA) to evaluate efficacy and safety of AZD1163.
Loading trial locations…
AstraZeneca Clinical Study Information Center
1-877-240-9479
information.center@astrazeneca.com
CONTACT